

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020**SECTION 1. IDENTIFICATION**

Product name : GAVRETO(TM) Capsules 100 mg
Product code : RO749-9790/F02
Common name(s),
synonym(s) of the substance : GAVRETO Capsules (hard) 100 mg

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.
Address : 1 DNA Way
South San Francisco, CA 94080
USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone
Emergency telephone : US Chemtrec phone (800)-424-9300
number


Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Carcinogenicity : Category 2
Reproductive toxicity : Category 2
Specific target organ toxicity : Category 2 (Cardiovascular, Skeleton, hematopoietic system)
- repeated exposure

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H351 Suspected of causing cancer.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Cardiovascular, Skeleton,
hematopoietic system) through prolonged or repeated exposure.

GAVRETO(TM) Capsules 100 mg
Version
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

Precautionary Statements : **Prevention:**
 P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read and understood.
 P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
 P405 Store locked up.

Disposal:
 P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Pralsetinib	2097132-94-8	21.8
Cellulose, 2-hydroxypropyl methyl ether	9004-65-3	>= 20.0 - <= 25.0
Carbonic acid sodium salt (1:1)	144-55-8	>= 15.0 - <= 20.0
1,2,3-Propanetricarboxylic acid, 2-hydroxy-	77-92-9	>= 5.0 - < 10.0
Cellulose	9004-34-6	>= 5.0 - < 10.0
Octadecanoic acid, magnesium salt (2:1)	557-04-0	< 1.0
Starch	9005-25-8	>= 1.0 - < 5.0
Titanium oxide (TiO ₂)	13463-67-7	< 0.5
non hazardous compounds	Not Assigned	> 20.0

SECTION 4. FIRST AID MEASURES

General advice : Move out of dangerous area.
 Show this material safety data sheet to the doctor in attendance.
 Do not leave the victim unattended.

If inhaled : Move to fresh air.
 If unconscious, place in recovery position and seek medical advice.
 If symptoms persist, call a physician.

GAVRETO(TM) Capsules 100 mg

Version 1.2	Revision Date: 04-20-2021	Date of last issue: 12-03-2020 Date of first issue: 11-30-2020
----------------	------------------------------	---

- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
Keep eye wide open while rinsing.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Take victim immediately to hospital.
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : Suspected of causing cancer.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire fighting : Do not allow run-off from fire fighting to enter drains or water courses.
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Hydrogen fluoride
Carbon oxides
- Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains.
Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Avoid dust formation.
Avoid breathing dust.
Avoid exposure

GAVRETO(TM) Capsules 100 mg

Version
1.2

Revision Date:
04-20-2021

Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

- Environmental precautions : Prevent product from entering drains.
Prevent further leakage or spillage if safe to do so.
If the product contaminates rivers and lakes or drains inform respective authorities.
- Methods and materials for containment and cleaning up : Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

- Advice on protection against fire and explosion : Avoid dust formation.
Provide appropriate exhaust ventilation at places where dust is formed.
- Advice on safe handling : Avoid formation of respirable particles.
Do not breathe vapors/dust.
Avoid exposure - obtain special instructions before use.
Avoid contact with skin and eyes.
For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.
Dispose of rinse water in accordance with local and national regulations.
- Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.
Electrical installations / working materials must comply with the technological safety standards.
- Further information on storage conditions : See label, package insert or internal guidelines
- Storage temperature : Protected from heat and light
Protect from moisture.
- Further information on storage stability : No decomposition if stored and applied as directed.
- Packaging material : Suitable material: Stainless steel, glass, Plastic container of HDPE

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Pralsetinib	2097132-94-8	IOEL	0.003 mg/m ³	Roche Industrial Hygiene Committee

GAVRETO(TM) Capsules 100 mg
Version
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

Cellulose	9004-34-6	TWA	10 mg/m ³	(RIHC) ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
		TWA (Total dust)	15 mg/m ³	OSHA P0
		TWA (respirable dust fraction)	5 mg/m ³	OSHA P0
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
		TWA (Total dust)	15 mg/m ³	OSHA P0
		TWA (respirable dust fraction)	5 mg/m ³	OSHA P0
Titanium oxide (TiO ₂)	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (Total dust)	10 mg/m ³	OSHA P0
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH
Octadecanoic acid, magnesium salt (2:1)	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : No data available

Personal protective equipment

Respiratory protection : In the case of dust or aerosol formation use respirator with an approved filter.
Effective dust mask

Hand protection

In case of contact through splashing:

GAVRETO(TM) Capsules 100 mg

Version 1.2	Revision Date: 04-20-2021	Date of last issue: 12-03-2020 Date of first issue: 11-30-2020
----------------	------------------------------	---

Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:
Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.
Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Eye wash bottle with pure water
Tightly fitting safety goggles

Skin and body protection : Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Protective measures : Instruction of employees mandatory

Hygiene measures : When using do not eat or drink.
When using do not smoke.
Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : capsules

Color : light blue

Odor : Not applicable

Odor Threshold : Not applicable

pH : Not applicable

Melting point/range : No data available

Boiling point/boiling range : No data available

Evaporation rate : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

Relative vapor density	:	Not applicable
Relative density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	Not applicable
Viscosity, kinematic	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	No decomposition if stored and applied as directed.
Conditions to avoid	:	No data available
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Expert judgment
Acute inhalation toxicity	:	Acute toxicity estimate: > 200 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020**Components:****Pralsetinib:**

Acute oral toxicity : LD50 Oral (Rat): > 300 mg/kg
GLP: yes

NOAEL (No observed adverse effect level) (Rat): 300 mg/kg
GLP: yes

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:

Acute oral toxicity : LD50 Oral (Rat): > 6,730 mg/kg

LD50 Oral (Rabbit): > 7,000 mg/kg

LD50 Oral (Mouse): 5,400 mg/kg

Cellulose:

Acute oral toxicity : LD50 Oral (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 Dermal (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : Acute toxicity estimate: > 5,001 mg/kg
Method: Expert judgment

Acute inhalation toxicity : Acute toxicity estimate: > 30 mg/l
Test atmosphere: dust/mist
Method: Expert judgment

Acute dermal toxicity : Acute toxicity estimate: > 5,001 mg/kg
Method: Expert judgment

Titanium oxide (TiO₂):

Acute oral toxicity : LD50 (Rat): > 7,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 10,000 mg/kg

Octadecanoic acid, magnesium salt (2:1):

Acute oral toxicity : LD50 Oral (Rat): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**1,2,3-Propanetricarboxylic acid, 2-hydroxy-:**

Remarks : May cause skin irritation in susceptible persons.

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020**Serious eye damage/eye irritation**

Not classified based on available information.

Components:**1,2,3-Propanetricarboxylic acid, 2-hydroxy-:**Result : Irritating to eyes.
Remarks : May cause irreversible eye damage.**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Pralsetinib:**Genotoxicity in vitro : Test Type: Ames test
Method: OECD Test Guideline 471
Result: negative
GLP: yesGenotoxicity in vivo : Test Type: Micronucleus test
Method: OECD Test Guideline 474
Result: negative
GLP: yes**Carcinogenicity**

Suspected of causing cancer.

Components:**Cellulose:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC Group 2B: Possibly carcinogenic to humans
Titanium oxide (TiO₂) 13463-67-7**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.**Reproductive toxicity**

Suspected of damaging the unborn child.

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020**Components:****Pralsetinib:**

Effects on fetal development : Test Type: reproductive and developmental toxicity study
Species: Rat, male and female
Application Route: Oral
Target Organs: Kidney
Result: Teratogenic potential.
GLP: yes

Test Type: reproductive and developmental toxicity study
Species: Rat, male and female
Application Route: Oral
Target Organs: Skeleton
Result: Teratogenic potential.
GLP: yes

Test Type: reproductive and developmental toxicity study
Species: Rat, male and female
Application Route: Oral
Target Organs: Urinary tract
Result: Teratogenic potential.
GLP: yes

Test Type: reproductive and developmental toxicity study
Species: Rat, male and female
Application Route: Oral
Target Organs: Testes
Result: Teratogenic potential.
GLP: yes

Reproductive toxicity - Assessment : Suspected human reproductive toxicant

Suspected of damaging the unborn child.

STOT-single exposure

Not classified based on available information.

Components:**Starch:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

Octadecanoic acid, magnesium salt (2:1):

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

May cause damage to organs (Cardiovascular, Skeleton, hematopoietic system) through prolonged or repeated exposure.

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020**Components:****Pralsetinib:**

Target Organs : Cardiovascular
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Target Organs : Skeleton
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Target Organs : hematopoietic system
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Starch:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Octadecanoic acid, magnesium salt (2:1):

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity**Components:****Pralsetinib:**

Species : Rat
 : 20 mg/kg bw/day
 Application Route : Oral
 Exposure time : 13 Weeks
 GLP : yes

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:

NOAEL : 4,000 mg/kg
 Exposure time : 5d
 Number of exposures : 1

Aspiration toxicity

Not classified based on available information.

Components:**Starch:**

No data available

Octadecanoic acid, magnesium salt (2:1):

No data available

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****1,2,3-Propanetricarboxylic acid, 2-hydroxy-:**

- Toxicity to fish : LC0 (Carassius auratus (goldfish)): 625 mg/l
- Toxicity to daphnia and other aquatic invertebrates : LC100 (Daphnia magna (Water flea)): 85 mg/l
- Toxicity to algae/aquatic plants : EC0 (Scenedesmus quadricauda (Green algae)): 640 mg/l
- Toxicity to microorganisms : EC0 (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h

Ecotoxicology Assessment

- Acute aquatic toxicity : This product has no known ecotoxicological effects.
- Chronic aquatic toxicity : This product has no known ecotoxicological effects.
- Toxicity Data on Soil : Not expected to adsorb on soil.
- Other organisms relevant to the environment : No data available

Cellulose:**Ecotoxicology Assessment**

- Acute aquatic toxicity : This product has no known ecotoxicological effects.
- Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Starch:

- Toxicity to fish : LC50: > 100 mg/l
Exposure time: 96 h

Ecotoxicology Assessment

- Acute aquatic toxicity : This product has no known ecotoxicological effects.
- Chronic aquatic toxicity : This product has no known ecotoxicological effects.
- Toxicity Data on Soil : Not expected to adsorb on soil.
- Other organisms relevant to the environment : No data available

Titanium oxide (TiO2):

- Toxicity to fish : LC0 (Leuciscus idus (Golden orfe)): > 1,000 mg/l
Exposure time: 48 h

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020Toxicity to daphnia and other : EC0 (Daphnia magna (Water flea)): 3 mg/l
aquatic invertebrates Exposure time: 720 h**Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to : No data available
the environment**Octadecanoic acid, magnesium salt (2:1):****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to : No data available
the environment**Persistence and degradability****Components:****1,2,3-Propanetricarboxylic acid, 2-hydroxy-:**Biodegradability : Biodegradation: 98 %
Exposure time: 7 d
Method: OECD Test Guideline 302B**Bioaccumulative potential****Components:****Pralsetinib:**Partition coefficient: n- : log Pow: 3.0 (68 °F / 20 °C)
octanol/water pH: 5
Method: OECD Test Guideline 107
GLP: yeslog Pow: 4.0 (68 °F / 20 °C)
pH: 7
Method: OECD Test Guideline 107
GLP: yeslog Pow: 3.9 (68 °F / 20 °C)
pH: 9
Method: OECD Test Guideline 107
GLP: yes**1,2,3-Propanetricarboxylic acid, 2-hydroxy-:**

Partition coefficient: n- : log Pow: -1.72

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

octanol/water

Cellulose:Partition coefficient: n-
octanol/water : Remarks: No data available**Starch:**Partition coefficient: n-
octanol/water : Remarks: No data available**Titanium oxide (TiO₂):**Partition coefficient: n-
octanol/water : Remarks: No data available**Octadecanoic acid, magnesium salt (2:1):**Partition coefficient: n-
octanol/water : log Pow: 0.8
Method: OECD Test Guideline 107**Mobility in soil**

No data available

Other adverse effects**Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82
Protection of Stratospheric Ozone - CAA Section 602 Class I
Substances
Remarks: This product neither contains, nor was
manufactured with a Class I or Class II ODS as defined by the
U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A +
B).

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**Waste from residues : Do not contaminate ponds, waterways or ditches with
chemical or used container.
Send to a licensed waste management company.Contaminated packaging : Empty remaining contents.
Dispose of as unused product.
Empty containers should be taken to an approved waste
handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Carcinogenicity
Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM/ Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

GAVRETO(TM) Capsules 100 mg

Version 1.2	Revision Date: 04-20-2021	Date of last issue: 12-03-2020 Date of first issue: 11-30-2020
----------------	------------------------------	---

Cellulose	9004-34-6
Starch	9005-25-8
Titanium oxide (TiO2)	13463-67-7

Pennsylvania Right To Know

Cellulose, 2-hydroxypropyl methyl ether	9004-65-3
Pralsetinib	2097132-94-8
non hazardous compounds	Not Assigned
Carbonic acid sodium salt (1:1)	144-55-8
1,2,3-Propanetricarboxylic acid, 2-hydroxy-	77-92-9
Cellulose	9004-34-6
Starch	9005-25-8
Titanium oxide (TiO2)	13463-67-7

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium oxide (TiO2), which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Starch	9005-25-8
Titanium oxide (TiO2)	13463-67-7

The ingredients of this product are reported in the following inventories:

- DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
 - Pralsetinib
 - non hazardous compounds
- AICS : Not in compliance with the inventory
- NZIoC : Not in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Product contains substance(s) not listed on TSCA inventory.

SAFETY DATA SHEET

GAVRETO(TM) Capsules 100 mg

Version
1.2

Revision Date:
04-20-2021

Date of last issue: 12-03-2020
Date of first issue: 11-30-2020


TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

NFPA 704:



HMIS® IV:

HEALTH	*	2
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

- ACGIH : USA. ACGIH Threshold Limit Values (TLV)
- NIOSH REL : USA. NIOSH Recommended Exposure Limits
- OSHA P0 : USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 1910.1000
- OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
- ACGIH / TWA : 8-hour, time-weighted average
- NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
- OSHA P0 / TWA : 8-hour time weighted average
- OSHA Z-1 / TWA : 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International

GAVRETO(TM) Capsules 100 mgVersion
1.2Revision Date:
04-20-2021Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 04-20-2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2004